executive arbitration group inc.

1591 kenmore avenue
kenmore, new york 14217

NYS Entity Status
ACTIVE

NYS Filing Date
MARCH 01, 2013

NYS DOS ID#
4367537

County
ERIE

Jurisdiction
NEW YORK

Registered Agent
NONE

NYS Entity Type
DOMESTIC BUSINESS CORPORATION

Name History
2013 - EXECUTIVE ARBITRATION GROUP INC.









Buffer



submit to reddit

Telephone
n/a

Fax
n/a

Website
n/a

Email address
n/a

LinkedIn
n/a

Facebook
n/a

Google+
n/a

Twitter
n/a

Pinterest
n/a

Instagram
n/a



  • Around the Web

  • Anthem Confirms Swedish to Step Down as CEO
    Monday Nov 6, 2017

    Anthem Inc. has named the former chief executive of UnitedHealth Group Inc.’s insurance business, Gail Boudreaux, its new president and chief executive officer.

    Source: The Wall Street Journal: U.S. Business
  • NY AG presses TransUnion, Experian for cybersecurity details
    By DAVID KLEPPER, Associated Press - Tuesday Sep 19, 2017

    ALBANY, N.Y. (AP) — New York Attorney General Eric Schneiderman is pressing TransUnion and Experian to explain what cybersecurity they have in place to protect sensitive consumer information following a recent breach at Equifax that exposed the data of 143 million Americans.In letters to executives at the two credit monitoring companies, the Democratic attorney general asked them to describe their existing security systems as well as what changes they've made since the Equifax cyberattack."The unprecedented data breach experienced by Equifax Inc.

    Source: SFGATE.com: Tech News
  • Big Business Groups Affirm Support for Nafta Arbitration Panels
    Thursday Aug 24, 2017

    Three of the nation’s most prominent trade associations warned that any efforts to weaken arbitration panels at the heart of the North American Free Trade Agreement will undermine business support for Nafta renegotiations.

    Source: The Wall Street Journal: U.S. Business
  • Uber’s former CEO names two board members amid legal fight
    By Eric Newcomer - Friday Sep 29, 2017

    Travis Kalanick, the co-founder and former chief executive officer of Uber Technologies Inc., said he has appointed Ursula Burns, Xerox Corp.’s former CEO, and John Thain, the ex-Merrill Lynch chief, to the startup’s board. Dara Khosrowshahi, Uber’s new CEO, challenged the appointments, calling them “a complete surprise.” Kalanick is defending himself against a lawsuit brought by Uber’s largest shareholder, Benchmark Capital, over his authority to appoint the two directors. Kalanick says he controls three of the company’s 11 board seats. Benchmark is suing Kalanick for fraud and has asked him to relinquish control of those positions. The suit is in arbitration.

    Source: SFGATE.com: Business and Technology News
  • Publisher Tronc acquires Daily News, storied NY tabloid
    By JENNIFER PELTZ, Associated Press - Monday Sep 4, 2017

    NEW YORK (AP) — Newspaper publisher Tronc has acquired the Daily News, a storied New York tabloid newspaper that won a Pulitzer Prize this year but has been buffeted by the changing media environment.Chicago-based Tronc Inc., the publisher of the Los Angeles Times and the Chicago Tribune, announced the deal Monday night, and the Daily News posted a story on its website.Tronc CEO Justin Dearborn said acquiring the paper and its popular website would "provide us with another strategic platform for growing our digital business, expanding our reach and broadening our services for advertisers and marketers," and both Tronc and Daily News executives said the company would maintain the quality of the paper's journalism.

    Source: SFGATE.com: Top News Stories
  • Aimmune in Brisbane teams with Regeneron to find peanut allergy cure
    By Caroline Chen - Tuesday Oct 17, 2017

    Aimmune Therapeutics Inc. is teaming with Regeneron Pharmaceuticals Inc. in hopes of developing a cure for peanut allergies. Aimmune, based in Brisbane, specializes in food allergy treatments and has been developing a desensitizing therapy, AR101, to protect peanut allergy sufferers against reactions from accidental exposures. By combining AR101 with Regeneron’s inflammation-inhibiting drug Dupixent, the companies are seeking to increase protection enough so patients stop reacting to peanuts even after treatment ends. “What we’re learning is that the immune system does seem to be plastic, and with the right group, you can turn the disease back,” Aimmune’s chief executive officer, Stephen Dilly, said.

    Source: SFGATE.com: Business and Technology News